Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals plc (JAZZ) had a Form 144 filed indicating that director Jennifer E. Cook may sell up to 3,507 shares of Jazz common stock under Rule 144. The shares relate to restricted stock vesting dated 08/28/2026, with an indicated aggregate market value of $857,602.00, to be sold through E*TRADE Financial on NASDAQ.
Jazz Pharmaceuticals plc (JAZZ) is the issuer for a planned sale of its common stock reported under Rule 144. Director Heather Ann McSharry, through an account at E*TRADE Financial, filed notice to sell up to 3,507 shares of JAZZ common stock, with an indicated aggregate market value of $857,602.00. The filing ties these shares to restricted stock vesting on 08/28/2026, and lists NASDAQ as the trading market. The proposed sale date is stated as 08/31/2026.
Jazz Pharmaceuticals plc (JAZZ) is the issuer of common stock that director Bruce C. Cozadd plans to sell under Rule 144. The notice covers a proposed sale of 2,506 common shares through E*TRADE, with an indicated market value of $612,817.00 as of August 31, 2026. The securities to be sold arise from restricted stock vesting treated as compensation. Cozadd has also reported sales totaling 18,000 common shares over the prior three months, on June 1, July 1, and August 3, 2026, for stated dollar amounts.
Jazz Pharmaceuticals plc (JAZZ) officer Robert Iannone has filed a notice to sell common shares under Rule 144. The filing states an intention to sell 76,921 shares of JAZZ common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $19,207,099.95 and JAZZ common shares outstanding of 64,914,577 as of the planned sale date of August 27, 2026. The shares to be sold were acquired through an employee stock purchase plan, performance shares, stock option exercises, and restricted stock awards, including awards vesting between March 5, 2026 and June 30, 2026.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. FDA approved two Ziihera® (zanidatamab-hrii)-containing regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The regimens are Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy, and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy.
The HERIZON-GEA-01 Phase 3 trial showed that Ziihera-based combinations reduced the risk of disease progression or death by 35%, extending median progression-free survival to 12.4 months vs. 8.1 months with trastuzumab plus chemotherapy. Ziihera plus tislelizumab and chemotherapy reduced risk of death by 28% and achieved median overall survival of 26.4 months vs. 19.2 months, the longest reported in a Phase 3 trial in this setting.
Ziihera regimens showed a manageable but significant safety burden, with high rates of diarrhea, infusion-related reactions and left ventricular dysfunction, and Boxed Warnings for diarrhea and embryo-fetal toxicity. Jazz plans an investor webcast on August 25, 2026 to discuss the approval and the broader zanidatamab development program.
Jazz Pharmaceuticals Public Limited Company entered into an Agreement and Plan of Merger under which its wholly owned subsidiary will acquire Actio Biosciences, Inc. via a merger, with Actio surviving as a wholly owned subsidiary. The consideration includes an initial Aggregate Upfront Transaction Value based on $820,000,000, adjusted for cash, transaction expenses, indebtedness, taxes, and other specified liabilities, allocated per share through an Upfront Per Share Amount.
Holders of Actio capital stock, non-underwater options and non-underwater warrants will also be entitled to contingent milestone payments of up to $500,000,000 in the aggregate. These milestones comprise a $250,000,000 payment upon regulatory approval of ABS-1230 for KCNT1-Related Epilepsy, a $100,000,000 payment upon first achievement of $500,000,000 in annual net sales of ABS-1230 products, and a $150,000,000 payment upon first achievement of $1,000,000,000 in annual net sales. Closing is subject to customary conditions, including Hart-Scott-Rodino clearance, required company stockholder approvals, completion of a spin-out of non-ABS-1230 programs to a new SpinCo in which Jazz will hold a minority stake, absence of a Material Adverse Effect, and specified employment and closing deliverables.
Jazz Pharmaceuticals plc entered into a definitive agreement to acquire privately held Actio Biosciences, Inc. for $820 million upfront plus up to $500 million in contingent approval and sales milestones. The deal adds Actio’s lead asset ABS-1230, a first-in-class KCNT1 ion channel inhibitor for KCNT1-related epilepsy, to Jazz’s rare epilepsy portfolio.
KCNT1+ epilepsy is a rare developmental and epileptic encephalopathy affecting approximately 2,500 patients in the U.S., with no FDA-approved therapies. ABS-1230 has shown meaningful seizure reductions in an early proof-of-concept trial and is being studied in the ongoing Phase 1b/2a KYRON trial, which is designed as the registrational study to support a U.S. new drug application.
ABS-1230 holds FDA Fast Track, Rare Pediatric Disease and Orphan Drug Product designations and is part of the FDA’s Rare Disease Evidence Principles program. At closing, Actio will spin out a new rare neurology company retaining other assets such as ABS-0871, with Jazz receiving a minority stake. The transaction, unanimously approved by both boards, is expected to close by the fourth quarter of 2026, funded by Jazz through cash and existing financing facilities, subject to customary closing conditions.
Jazz Pharmaceuticals executive Samantha Pearce, EVP and Chief Commercial Officer, reported that 780 Ordinary Shares were withheld on 2026-08-05 at $261.62 per share to satisfy tax obligations from vesting of previously granted restricted stock units. After this tax-withholding disposition, she directly holds 47,131 Ordinary Shares.
Winningham Rick E reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Rick E Winningham reported an equity award of 1,605 restricted stock units, each representing one ordinary share, granted at $0.0000 per share under the 2007 Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 11,172 ordinary shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Ted W. Love received a grant of 1,605 restricted stock units, each representing a contingent right to receive one ordinary share at a cash price of $0.00 per share.
The award was granted under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to his continuous service and other conditions. Following this grant, Love directly holds 3,132 ordinary shares.